Monday, November 9, 2026

USD/CNH Bearish By 1% In The Last 10 Sessions

USD/CNH Bearish By 1% In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.95% for the last 10 sessions. At 18:09 EST on Tuesday, 12 March, USD/CNH (USDCNH) is $7.19.

USD/CNH's yearly highs and lows, it's 0.04% up from its 52-week low and 0.004% down from its 52-week high.

News about

  • According to FXStreet on Tuesday, 12 March, "This, in turn, will drive the USD demand in the near term and provide a fresh directional impetus to the USD/JPY pair.", "A sustained strength beyond, however, could lift the USD/JPY pair beyond the 148.00 mark, towards testing the next relevant hurdle near the 148.65-148.70 region. "
  • According to FXStreet on Tuesday, 12 March, "Likely, the narrowing of the spreads between the US and Japan and the Eurozone and Japan (even though most of it is already anticipated) lead to lower levels in USD/JPY and EUR/JPY."
  • Usd/jpy has risen in the first hour after the last three US CPI report releases by an average of +0.57% – MUFG. According to FXStreet on Tuesday, 12 March, "Looking back at the performance of USD/JPY just after the release of US CPI reports, there has been a clear trend for USD/JPY to strengthen in recent months. ", "The performance of USD/JPY will be driven today by the release of the latest US Consumer Price Index (CPI) report for February, economists at MUFG Bank say."
  • Usd/jpy analysis: bearish week awaits US and Japan data - 11 March 2024. According to DailyForex on Monday, 11 March, "Based on the performance on the daily chart there has been a clear breach of the overall uptrend for the USD/JPY currency pair. ", "A break below the support level of 145.90 confirms bearish control over the USD/JPY direction. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com